Clinical Trials Directory

Trials / Completed

CompletedNCT03642665

Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer

Frozen-thawed Embryo Transfer in a Natural Versus Artificial Cycle: a Randomized Clinical Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
554 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

This study evaluates clinical pregnancy rates, obstetrical outcome parameters, costs and patient preferences in natural cycle versus artificial cycle frozen embryo transfers (FET).

Detailed description

Transfer of cryopreserved embryos can be performed in a natural cycle (NC-FET) or in an artificially prepared cycle (AC-FET). Both cycle regimens have their advantages and disadvantages. So far, most comparative studies have failed to identify the optimal protocol for FET. In this study patients undergoing FET will be randomized between an endometrial preparation by a natural cycle or by an artificial cycle (by oestradiol validate and micronized progesterone).

Conditions

Interventions

TypeNameDescription
DRUGNatural cycleno medication
DRUGEstradiol ValerateOestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
DRUGMicronized progesteroneMicronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.

Timeline

Start date
2018-09-25
Primary completion
2024-11-01
Completion
2024-11-01
First posted
2018-08-22
Last updated
2025-02-28

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03642665. Inclusion in this directory is not an endorsement.